Sponsors (6)
The bill delivers meaningful, standardized two‑year Medicaid coverage of OTC meds and wound supplies for people with EB—greatly reducing costs and improving care for beneficiaries in the short term—but it is temporary, may leave some patients out depending on eligibility rules, and will increase Medicaid spending and administrative workload during the demonstration.
Medicaid beneficiaries with epidermolysis bullosa (EB) receive guaranteed coverage of OTC medications and wound supplies for two years, reducing their out‑of‑pocket costs and immediate financial burden.
People with EB are likely to experience fewer wound‑related complications and hospitalizations because expanded coverage improves access to necessary wound‑care supplies, improving health outcomes.
The nationwide demonstration standardizes access to EB-related OTC meds and supplies across states for the demonstration period, reducing geographic disparities in coverage.
The program is only a two‑year demonstration, so people with EB may lose expanded coverage after the demo ends, delaying permanent nationwide access to needed supplies.
If the demonstration’s eligibility or benefit criteria are narrowly defined, some individuals with EB could remain without needed coverage despite the program, perpetuating coverage gaps.
The demonstration will likely increase Medicaid spending over the demonstration period, which could raise costs for federal/state budgets and taxpayers or require shifting funds from other programs.
Based on analysis of 4 sections of legislative text.
Requires a nationwide 2-year Medicaid demonstration to cover specified wound-care medicines and supplies for treating epidermolysis bullosa and requires an HHS report evaluating costs and outcomes.
Introduced March 9, 2026 by Greg Landsman · Last progress March 9, 2026
Requires HHS to run a nationwide, two-year demonstration that makes Medicaid pay for specific wound-care medicines and supplies used to treat epidermolysis bullosa (EB) for eligible Medicaid beneficiaries. The demo must begin within one year of enactment and HHS must report to Congress within one year after the demo ends on costs, health outcomes compared to before the demo, and recommendations to prevent related hospitalizations.